← board
APUS
distress 7/10 · high distress / dilution risk$0.68+3%today-83% from 52w high
Revenue
pre-revenue
Liquidity
$2M
Runway
0.2 yrs
Shares 1y
+20%
Price & events
-67.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.0%
1D
+3.8%
1W
-23.6%
1M
-63.8%
3M
-68.8%
6M
-68.8%
1Y
—
2Y
—
5Y
-69.1%
All
Overview
- Market Cap
- $10.26M
- Volume
- 7.17K
- 52 Week Range
- $0.65 – $3.90
- Total Shares
- 15.09M
- Short %
- 2.87%
- % Held by Insiders
- 52.58%
- % Held by Institutions
- 2.97%
- RVOL
- 0.05x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025-12-01partnershipMerger of Apimeds and MindWave Innovations, with Apimeds issuing stock to former MindWave stockholders.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.